1 terminated. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow BioXcellerator: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19 Wharton's jelly derived Mesenchymal stem cells., Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy) - Acute Respiratory Distress Syndrome | Phase 1 / Phase 2 | Terminated | BioXcellerator | 6 | 2020-01-13 | 2024-08-27 |
Coronavirus Infections (1) · Respiratory Distress Syndrome (1)
Azithromycin (1) · Hydroxychloroquine (1) · Lopinavir (1) · Ritonavir (1) · Standard of Care (1)
Colombia (1)